Company news

Filament Health Corp news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Filament Health announces voluntary delisting from Cboe Canada

May 19, 2025

Filament Health announces first quarter 2025 financial results and operational highlights

May 8, 2025

Filament Health announces FDA authorization of phase 2 clinical trial studying PEX010, the company's botanical psilocybin drug candidate, in opioid use disorder

April 9, 2025

Filament Health announces private placement and intention to voluntarily delist from Cboe Canada

April 3, 2025

Filament Health reports Q4 and year end 2024 financial results and operational highlights

April 1, 2025

Filament Health announces positive data from phase 2 study of PEX010 in patients with alcohol use disorder

March 17, 2025

Filament Health announces shipment of botanical psilocybin to the University of wisconsin-madison

January 21, 2025

Filament Health announces import of coca leaf from Peru by joint venture magdalena biosciences

December 16, 2024

Filament Health announces third quarter 2024 financial results and Operational Highlights

November 14, 2024

Filament Health announces issuance of common shares to negev capital investments limited pursuant to advisory agreement

October 4, 2024

Filament Health announces second quarter 2024 Financial results and Operational Highlights

August 14, 2024

Filament Health announces major intellectual property expansion

August 13, 2024

Filament Health announces closing of warrant exercise, note conversion and concurrent private placement of common shares

June 12, 2024

Filament Health announces authorization of phase 2 clinical trial for PEX010 in the treatment of methamphetamine use disorder

June 3, 2024

Filament Health announces warrant exercise and note conversion by negev capital and concurrent private placement of common shares to Benjamin Lightburn, Chief Executive Officer

June 3, 2024

Filament Health announces first quarter 2024 financial results and Operational Highlights

May 14, 2024

Filament Health announces change to board of directors

May 3, 2024

Filament Health to discuss its drug development platform in fireside chat with water tower research on April 4, 2024 at 12PM et

April 3, 2024

Filament Health reports Q4 and year end 2023 financial results and operational highlights

April 2, 2024

Filament Health announces appointment of Michael Messinger to its board of directors

March 28, 2024

Filament Health announces shipments of botanical psilocybin to four countries for clinical investigation

March 19, 2024

Filament Health announces FDA opening of IND application for substance abuse disorder

February 20, 2024

Filament Health completes the first export of botanical psilocybin to Israel

February 15, 2024

Filament Health announces FDA opening of investigational new drug application for substance use disorders

January 31, 2024

Filament Health completes the first export of botanical psilocybin to Australia

January 17, 2024

Filament Health announces change to board of directors

January 2, 2024

Filament Health announces termination of proposed business combination with jupiter acquisition corporation

December 20, 2023

Filament Health announces termination of shareholder meeting and engagement of donohoe advisory for compliance expertise

December 18, 2023

Filament Health announces adjournment of special meeting

December 11, 2023

Filament Health files amended pro forma financial statements

December 7, 2023

Filament Health announces signing of definitive agreement for convertible note financing, closing of C$900,000 non-brokered private placement financing, founder-led note offering and other updates related to upcoming special meeting and Proposed Business Combination

December 6, 2023

Filament Health announces non-binding agreement for up to US$14 million in financing

November 29, 2023

Filament Health receives authorization from Health Canada for Phase 2 clinical trial at UBC

November 29, 2023

Filament Health signs non-binding term sheet for convertible note in connection with planned Business Combination

November 23, 2023

Filament Health announces third quarter 2023 financial results and Operational Highlights

November 14, 2023

Filament Health and NASDAQ-listed spac jupiter acquisition corporation announce Form F-4 registration statement declared effective by the U.S. securities and Exchange Commission and mailing of definitive proxy statement

November 14, 2023

Filament Health Announces Annual General Meeting Voting Results

November 8, 2023

Filament Health announces Health Canada authorization for phase 2 clinical trial studying botanical psilocybin for opioid use disorder

October 10, 2023

Filament Health Corp. announces non-brokered private placement unit offering led by Negev Capital

September 29, 2023

Filament Health and jaguar health joint venture magdalena biosciences completes import of coca leaf from Peru

September 21, 2023

Filament Health enters licensing agreement with reset pharma

August 31, 2023

Filament Health and NASDAQ-listed SPAC jupiter acquisition corp. announce filing of SEC registration statement

August 15, 2023

Filament Health announces first quarter 2023 financial results and refiles Q1 2023 interim financial statements and MD&A

August 15, 2023

Filament Health announces FDA approval of two clinical trials studying its botanical psilocybin drug candidate PEX010

August 8, 2023

Filament Health announces upsizing and closing of $2,500,000 non-brokered private placement financing

July 24, 2023

Filament Health Corp. announces non-brokered private placement unit offering of up to C$2,000,000

July 19, 2023

Filament Health Corp. to list on NASDAQ through business combination with jupiter acquisition corporation

July 19, 2023

Filament Health announces change of auditor

July 14, 2023

Filament Health to supply psilocybin for recipients of The Canadian Institutes of Health Research psilocybin Operating Grants

July 6, 2023

Filament Health enters exclusive licensing agreement with NeoLumina bioscience inc.

June 30, 2023

Older news releases →

Decks